HIV vaccine candidate VIR-1388 passes early safety check in 93 volunteers

NCT ID NCT05854381

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 32 times

Summary

This study tested a new HIV vaccine called VIR-1388 in 93 healthy adults who did not have HIV. The goal was to see if the vaccine is safe and whether it triggers an immune response. Participants were randomly assigned to receive either the vaccine or a placebo, and researchers monitored them for side effects and immune cell activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV I INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alabama CRS

    Birmingham, Alabama, 35222, United States

  • Beth Israel Deconess Medical Center VCRS

    Boston, Massachusetts, 32077, United States

  • Chatsworth Clinical Research Site

    Overport, KwaZulu-Natal, 4092, South Africa

  • Isipingo Clinical Research Site

    Isipingo, KwaZulu-Natal, 4110, South Africa

  • Penn Prevention CRS

    Philadelphia, Pennsylvania, 19104, United States

  • Perinatal HIV Research Unit

    Soweto, Gauteng, 1862, South Africa

  • Seattle Vaccine and Prevention CRS

    Seattle, Washington, 98104, United States

  • Setshaba Research Centre CRS

    Soshanguve, Gauteng, 0152, South Africa

  • The Hope Clinic of the Emory Vaccine Center CRS

    Decatur, Georgia, 30030, United States

  • University of Pittsburgh CRS

    Pittsburgh, Pennsylvania, 15213, United States

Conditions

Explore the condition pages connected to this study.